Plus Therapeutics presented an update on its ReSPECT-GBM Phase 1/2 clinical trial for recurrent glioblastoma on September 30, 2024. The data highlighted the continued favorable safety profile and encouraging efficacy results of Rhenium (186 Re) Obisbemeda in patients with a historically poor prognosis.
The mean absorbed dose in Phase 2 was 300 Gy, with 89% of patients exceeding the minimal dose threshold of 100 Gy. This demonstrates the drug's ability to deliver high, targeted radiation doses.
The ReSPECT-GBM Phase 1/2 trial has expanded to include two new sites at leading U.S. academic medical centers: North Shore University in New York and Ohio State University. This expansion aims to accelerate patient enrollment and advance the study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.